News - Page 39 - Psychedelic Alpha

Our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts are now available.

Read more about the article Psychedelic Research Bulletin: July and August 2023

Psychedelic Research Bulletin: July and August 2023

Post published:September 9, 2023
Post category:News Psychedelics Research Review

Read more about the article Optimi Health Granted Amendment to Dealer's Licence by Health Canada to Supply Special Access Program

Optimi Health Granted Amendment to Dealer's Licence by Health Canada to Supply Special Access Program

Post published:September 7, 2023
Post category:Press Release

Read more about the article atai Life Sciences to Participate in Upcoming September Investor Conferences

atai Life Sciences to Participate in Upcoming September Investor Conferences

Post published:September 6, 2023
Post category:Press Release

Read more about the article Clearmind Medicine Announces Clinical Research Collaboration with Johns Hopkins University to Evaluate CMND-100 in Patients with Alcohol Use Disorder

Clearmind Medicine Announces Clinical Research Collaboration with Johns Hopkins University to Evaluate CMND-100 in Patients with Alcohol Use Disorder

Post published:September 6, 2023
Post category:Press Release

Read more about the article Algernon Pharmaceuticals Announces Grant of U.S. Patent for Repirinast in NAFLD and NASH

Algernon Pharmaceuticals Announces Grant of U.S. Patent for Repirinast in NAFLD and NASH

Post published:September 6, 2023
Post category:Press Release

Read more about the article PharmaTher Submits Priority Original Abbreviated New Drug Application for KETARX™ (Ketamine) to the FDA

PharmaTher Submits Priority Original Abbreviated New Drug Application for KETARX™ (Ketamine) to the FDA

Post published:September 6, 2023
Post category:Press Release

Read more about the article COMPASS Pathways announces publication of first study evaluating potential of AI model to predict outcomes of COMP360 psilocybin treatment in treatment-resistant depression

COMPASS Pathways announces publication of first study evaluating potential of AI model to predict outcomes of COMP360 psilocybin treatment in treatment-resistant depression

Post published:September 6, 2023
Post category:Press Release

Read more about the article BetterLife Highlights BETR-001 Article in Technology Networks Drug Discovery and Announces Closing of a Private Placement

BetterLife Highlights BETR-001 Article in Technology Networks Drug Discovery and Announces Closing of a Private Placement

Post published:September 5, 2023
Post category:Press Release

Read more about the article Optimi Health Announces Second Tranche of CAD $1,000,000 Secured for Debt Financing

Optimi Health Announces Second Tranche of CAD $1,000,000 Secured for Debt Financing

Post published:September 5, 2023
Post category:Press Release

Read more about the article California Psychedelic Decriminalisation Bill Clears Appropriations Committee with Amendments

California Psychedelic Decriminalisation Bill Clears Appropriations Committee with Amendments

Post published:September 1, 2023
Post category:News

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond. Psy Alpha Ltd is a company registered in England and Wales (16989109).

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.